Baricitinib, Tildrakizumab-asmn, and Elagolix sodium. [electronic resource]
Producer: 20190917Description: 685-688 p. digitalISSN:- 1544-3450
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.